KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.90

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial.

Xavier Serra-Aracil, Carles Pericay, Ariadna Cidoncha, Jesus Badia-Closa, Thomas Golda, Esther Kreisler, Pilar Hernández, Eduardo Targarona, Nerea Borda-Arrizabalaga, Angel Reina, Salvadora Delgado, Eloy Espín-Bassany, Aleidis Caro-Tarrago, Javier Gallego-Plazas, Marta Pascual, Carlos Álvarez-Laso, Hector Guadalajara-Labajo, Ana Otero, Sebastiano Biondo, TAUTEM Collaborative Group

JAMA Surg 160(7) 783-793

PMID40434784
PMCIDPMC12120676
DOI10.1001/jamasurg.2025.1398
发表日期2025-05-28
入排依据:The trial is a Phase III randomized controlled trial in oncology with human patients and time-to-event efficacy endpoints (OS, DFS). However, the experimental intervention (chemoradiotherapy + local excision) and the control intervention (total mesorectal excision) are both non-drug-only treatments (radiotherapy and/or surgery). No drug-containing intervention is explicitly reported, which is a required criterion for eligibility.
摘要

摘要

IMPORTANCE: According to international guidelines, the standard treatment for stage T2-T3ab, N0, M0 rectal cancer is total mesorectal excision (TME), but it is associated with high morbidity and quality of life disorders. OBJECTIVE: To analyze locoregional recurrence (LR) after a follow-up of 2 years, applying a 1-sided noninferiority margin of 10%, and to assess distant recurrence (DR), overall survival (OS), and disease-free survival (DFS). DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, prospective, open-label, noninferiority, phase 3 randomized clinical trial comparing TME (TME group) with chemoradiotherapy followed by local excision with transanal endoscopic microsurgery (CRT-TEM group). This study involved 17 hospitals in Spain. Eligibility criteria included patients with rectal adenocarcinoma located lower than 10 cm from the anal verge; stage T2-T3ab N0, M0; tumor size less than or equal to 4 cm in diameter; and American Society of Anesthesiologists stage III or less with no metastasis. Sample size was calculated with a 1-sided significance level of 2.5% and a power of 80%, assuming a nonrecurrence rate of 95% in each arm and a possible loss of 15%. Randomization was performed with a 1:1 allocation ratio. Data were analyzed from July 2010 to October 2021. INTERVENTIONS: The 2 treatment groups were CRT-TEM and TME. MAIN OUTCOMES AND MEASURES: The main study outcome was LR. RESULTS: From July 2010 to October 2021, 173 patients (median [IQR] age, 67 [59-75] years; 116 male [67.1%]) were included (CRT-TEM, n = 86; TME, n = 87). In the 5-year modified intention-to-treat analysis, LR was 6.2% (5 of 81 patients) in the TME group and 7.4% (6 of 81 patients) in the CRT-TEM group (difference, -1.23%; 95% CI, 6.51% to -8.98%). DR was 17.3% (14 of 81 patients) in the TME group and 12.3% (10 of 81 patients) in the CRT-TEM group (difference, 4.94%; 95% CI, 15.85% to -5.98%). OS was 85.2% (69 of 81 patients) in the TME group and 82.7% (67 of 81 patients) in the CRT-TEM group (difference, 2.47%; 95% CI, 0.38%-1.78%). DFS in both groups was 88.9% (72 of 81), with a 95% CI of 9.68 to -9.68. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial reveal that CRT-TEM achieved noninferior results compared with standard TME treatment in terms of LR and similar results in terms of DR, OS, and DFS. CRT-TEM appears to be a suitable treatment option for patients with T2-T3ab, N0, M0 rectal cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01308190.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 3

Figure 3.. Overall Survival (3A), Disease-Free Survival (3B), and Rectal Cancer Mortality (3C), Among Patients Randomly Assigned to Total Mesorectal Excision (TME) vs Chemoradiotherapy and Transanal Endoscopic Microsurgery (CRT-TEM) According to Modified Intention-to-Treat Analyses HR indicates hazard ratio.

A

Overall survival

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:short span
查看结果
B

Disease-free survival

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
C

Mortality due to rectal cancer

Figure 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Consolidated Standards of Reporting Trials (CONSORT) Diagram AE indicates adverse event; CRT, chemoradiotherapy; ITT, intention to treat; MRI, magnetic resonance imaging; TEM, transanal endoscopic microsurgery; TME, total mesorectal excision.
非 KM Figure
Figure 2Figure 2.. Local (2A) and Distant Recurrences (2B) Among Patients Randomly Assigned to Total Mesorectal Excision (TME) vs Chemoradiotherapy and Transanal Endoscopic Microsurgery (CRT-TEM), According to Modified Intention-to-Treat (mITT) Analyses Tick marks on the curve indicate individuals whose data were censored. HR indicates hazard ratio.
非 KM Figure